MannKind Corporation (MNKD) Shares are Down -19.22%

MannKind Corporation (MNKD) : During the past 4 weeks, traders have been relatively bearish on MannKind Corporation (MNKD), hence the stock is down -20.18% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -18.68% relative to the S&P 500. The 4-week change in the price of the stock is -20.34% and the stock has fallen -19.22% in the past 1 week.

The shares have received a consensus rating of Sell for the current week The stock has recorded a twenty day Moving Average of 18.41% and the fifty day Moving Average is 23.92%. MannKind Corp. has dropped 18.78% during the last three month period . Year-to-Date the stock performance stands at -45.61%.


MannKind Corporation (NASDAQ:MNKD): On Fridays trading session , Opening price of the stock was $0.84 with an intraday high of $0.85. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.7707. However, the stock managed to close at $0.7886, a loss of 5.61% for the day. On the previous day, the stock had closed at $0.8355. The total traded volume of the day was 6,143,482 shares.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *